Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announces that it has entered into a definitive agreement to sell its whole blood assets to GVS, S.p.A (“GVS”), one of the world’s leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. The transaction comprises a total cash consideration of up to $67.1M, which includes $44.6M upfront and up to $22.5M in contingent earn-outs over the next four years.
Read the full article: Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A //
Source: https://www.prnewswire.com/news-releases/haemonetics-announces-sale-of-whole-blood-assets-to-gvs-spa-302320478.html